Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1–5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease. Mol Cancer Ther; 11(11); 2541–6. ©2012 AACR.

[1]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[2]  S. Amundson,et al.  Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression. , 2011, Experimental cell research.

[3]  Laurence Doyle,et al.  Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures , 2011, PloS one.

[4]  B. Alman,et al.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets , 2010, Nature Reviews Cancer.

[5]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Kurzrock,et al.  Chemotherapy resistance and retreatment: a dogma revisited. , 2010, Clinical colorectal cancer.

[7]  G. García‐Santos,et al.  Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. , 2010, Cancer letters.

[8]  P. Galle,et al.  TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. , 2009, World journal of gastroenterology.

[9]  Robert E. Brown,et al.  Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. , 2009, Archives of pathology & laboratory medicine.

[10]  L. Koniaris,et al.  Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. , 2009, The Journal of bone and joint surgery. American volume.

[11]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Dodd,et al.  The Clinical Management of Chondrosarcoma , 2009, Current treatment options in oncology.

[13]  A. Ashkenazi,et al.  Directing cancer cells to self-destruct with pro-apoptotic receptor agonists , 2008, Nature Reviews Drug Discovery.

[14]  Margit Rosner,et al.  Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. , 2008, Human molecular genetics.

[15]  K. Nishida,et al.  Chondrosarcoma and Peroxisome Proliferator-Activated Receptor , 2008, PPAR research.

[16]  R. Herbst,et al.  To kill a tumor cell: the potential of proapoptotic receptor agonists. , 2008, The Journal of clinical investigation.

[17]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[18]  L. Broemeling,et al.  Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies , 2006, Molecular Cancer Therapeutics.

[19]  R. Zeillinger,et al.  Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer , 2005, Molecular Cancer Research.

[20]  Robert E. Brown,et al.  Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients , 2005, Expert review of proteomics.

[21]  Jie Wu,et al.  Peroxisome proliferator-activated receptor γ ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines , 2005, Acta Pharmacologica Sinica.

[22]  H. Inoue,et al.  Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. , 2005, Biochemical and biophysical research communications.

[23]  A. Cleton-Jansen,et al.  Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas , 2005, The Journal of pathology.

[24]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[25]  B. Aggarwal,et al.  Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  A. Cleton-Jansen,et al.  Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma , 2000, Laboratory Investigation.

[27]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.